TY  - EJOU
AU  - Garfield, Susan S. 
AU  - Gavaghan, Meghan B. 
AU  - Armstrong, Shannon O. 
AU  - Jones, J. Stephen 

TI  - The cost-effectiveness of blue light cystoscopy in bladder cancer detection: United States  projections based on clinical data showing 4.5 years of follow up after a single hexaminolevulinate hydrochloride instillation
T2  - Canadian Journal of Urology

PY  - 2013
VL  - 20
IS  - 2
SN  - 1488-5581

AB  - <b>Introduction:</b> Several studies, including the recently published phase III study by Stenzl and colleagues, have demonstrated that hexaminolevulinate hydrochloride, when used with blue light fluorescence cystoscopy, improves detection of non-muscle invasive bladder tumors compared to white light cystoscopy and transurethral resection of bladder tumors (TURB) alone.<br/>
<b>Materials and methods:</b> The objective of this study was to conduct a detailed assessment of the cost-effectiveness of using hexaminolevulinate hydrochloride with blue light cystoscopy as an adjunct to white light versus white light cystoscopy alone at the time of initial TURB in the United States. A probabilistic decision tree model, using TreeAge Pro 2011 software, was developed using base case scenario cost and utility estimates.<br/>
<b>Results:</b> Incorporation of hexaminolevulinate hydrochloride into diagnostic cystoscopy results in lower costs over 5 years ($25,921) as compared to those patients who initially receive white light cystoscopy ($30,581). Those patients who initially receive hexaminolevulinate hydrochloride blue light TURB also experience a lower overall cancer burden.<br/>
<b>Conclusions:</b> Hexaminolevulinate hydrochloride may be cost-effective when used at first TURB for patients with suspected new or recurrent non-muscle invasive bladder cancer.
KW  - white light cystoscopy
KW  -  bladder cancer
KW  -   bladder cancer detection
KW  -  Cysview
KW  -  cystoscopy
KW  -  cost-effectiveness
KW  -  outcomes
KW  -  utility
KW  -  cystectomy
KW  -  transurethral resection of the bladder

DO  -